Home / Business and Economy / Jim Cramer Bets on Jazz Pharma Despite Stock Dip
Jim Cramer Bets on Jazz Pharma Despite Stock Dip
14 Oct
Summary
- Jim Cramer endorsed Jazz Pharmaceuticals on Mad Money.
- Jazz Pharma has three key revenue-generating products.
- Analysts set price targets significantly higher than current stock price.
Jim Cramer recently expressed confidence in Jazz Pharmaceuticals (JAZZ) during "Mad Money," advising a "yes" on the stock. This endorsement comes as JAZZ shares have experienced a recent pullback, closing at $218.42 on October 9, 2026, marking an approximate 11% decrease over the past month.
Despite the recent downturn, Jazz Pharmaceuticals remains profitable, driven by key products like Xywav for narcolepsy, Epidiolex for epilepsy, and the newly approved cancer therapy Ziihera. These drugs generated a record second-quarter revenue of $1.2 billion, with Xywav alone contributing $471.2 million.
Following the FDA approval of Ziihera in late August 2026, Jazz raised its peak sales estimate for the drug significantly. This positive development has led Wall Street analysts to issue updated price targets, with several firms setting targets between $300 and $310, well above the current stock price. However, investor success hinges on Ziihera's market adoption, including doctor prescription rates and insurer coverage, alongside facing competition in the HER2 cancer treatment space.
